Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 29
Filter
1.
Front Med (Lausanne) ; 10: 1189680, 2023.
Article in English | MEDLINE | ID: mdl-37153100

ABSTRACT

In the last two decades, the optimization of organ preservation and surgical techniques, and the personalized immunosuppression have reduced the rate of acute rejections and early post-transplant complications. However, long-term graft survival rates have not improved over time, and evidence suggest a role of chronic calcineurin inhibitor toxicity in this failure. Solid organ transplant recipients may develop chronic dysfunction/damage and several comorbidities, including post-transplant malignancies. Skin cancers, mostly non-melanoma skin cancers (squamous cell carcinoma and basal cell carcinoma), are the most common malignancies in Caucasian solid organ transplant recipients. Several factors, together with immunosuppression, may contribute to the susceptibility for skin cancers which, although often treatable, could be associated with a much higher mortality rate than in the general population. The rapid identification and treatment (including reduction of immunosuppression and early surgical treatments) have an important role to avoid an aggressive behavior of these malignancies. Organ transplant recipients with a history of skin cancer should be followed closely for developing new and metastatic lesions. Additionally, patient education on the daily use of sun-protective measures and the recognition of the early signs (self-diagnosis) of coetaneous malignancies are useful preventive measures. Finally, clinicians should make themselves aware of the problem and build, in every clinical follow-up center, collaborative network involving transplant clinicians, dermatologists and surgeons who should work together to easily identify and rapidly treat these complications. In this review, we discuss the current literature regarding the epidemiology, risk factors, diagnosis, preventive strategies and treatments of skin cancer in organ transplantation.

2.
Exp Dermatol ; 31(2): 143-153, 2022 02.
Article in English | MEDLINE | ID: mdl-34331820

ABSTRACT

The mammalian target of rapamycin inhibitor (mTOR-I) Rapamycin, a drug widely used in kidney transplantation, exerts important anti-cancer effects, particularly in Kaposi's Sarcoma (KS), through several biological interactions. In this in vivo and in vitro study, we explored whether the activation of the autophagic pathway through the low-affinity receptor for nerve growth factor, p75NTR , may have a pivotal role in the anti-cancer effect exerted by Rapamycin in S. Our Kimmunohistochemistry results revealed a significant hyper-activation of the autophagic pathway in KS lesions. In vitro experiments on KS cell lines showed that Rapamycin exposure reduced cell viability by increasing the autophagic process, in the absence of apoptosis, through the transcriptional activation of p75NTR via EGR1. Interestingly, p75NTR gene silencing prevented the increase of the autophagic process and the reduction of cell viability. Moreover, p75NTR activation promoted the upregulation of phosphatase and tensin homolog (PTEN), a tumour suppressor that modulates the PI3K/Akt/mTOR pathway. In conclusion, our in vitro data demonstrated, for the first time, that in Kaposi's sarcoma, autophagy triggered by Rapamycin through p75NTR represented a major mechanism by which mTOR inhibitors may induce tumour regression. Additionally, it suggested that p75NTR protein analysis could be proposed as a new potential biomarker to predict response to Rapamycin in kidney transplant recipients affected by Kaposi's sarcoma.


Subject(s)
Sarcoma, Kaposi , Sirolimus , Apoptosis , Autophagy , Humans , Phosphatidylinositol 3-Kinases , Sarcoma, Kaposi/pathology , Sirolimus/pharmacology , TOR Serine-Threonine Kinases/metabolism
4.
Dermatology ; 237(6): 1039-1045, 2021.
Article in English | MEDLINE | ID: mdl-33979792

ABSTRACT

INTRODUCTION: Bullous pemphigoid (BP) is an autoimmune disease that typically presents with blisters, but sometimes early lesions may be eczematous, maculopapular, or urticarial. The aim of the present study was to highlight possible differences between typical bullous and non-bullous pemphigoid (NBP) and compare results with the literature. Material & methods: Patients receiving a diagnosis of BP between January 2000 and December 2019 were analyzed. Patients who developed a blister after 3 months from the onset of pruritus were considered as NBP. Demographic features, clinical findings at diagnosis and at 2-year follow-up, histological features, auto-antibodies titers, comorbidities and their treatment were retrieved. Categorical variables were evaluated for normal distribution using a histogram and a Q-Q plot. The χ2 and Fisher's exact tests were used to compare categorical variables between the groups. Continuous variables were compared between the groups using analysis of variance and the independent-samples t test. For multivariate analysis, logistic regression was performed. RESULTS: A total of 532 patients received a diagnosis of BP. A total of 122 patients were enrolled in the study; 63 were females, and the mean age at the diagnosis was 77.2 years (±11.9 SD). 98 were affected by BP and 24 were categorized as NBP. Mean time to diagnosis was 2.9 months (±5.8 SD) for BP and 30.4 months (±59.8 SD) for NBP (p = 0.0001). Skin manifestations in NBP patients were, in order of frequency: urticarial, papular or nodular, eczematous, and excoriations. Pruritus intensity was high but similar in the two groups (Numerical Rating Scale - NRS, 9.3 vs. 8.9). Seven out of 24 NBP patients (29%) never developed blisters; the other patients developed blisters after a mean follow-up time of 24.9 months (±54.9 SD). NBP patients had a more frequent history of myocardial infarction than BP patients (37.5 vs. 10.2%; p < 0.003). More NBP patients were taking diuretics than BP patients (66.7 vs. 49%; p = 0.03). NBP patients had a worse response to pruritus compared to BP patients at 2 years (NRS 3.7 vs. 11; p 0.001). CONCLUSIONS: NBP patients have a delayed diagnosis and may be at an increased risk of cardiovascular disease, especially myocardial infarction. Severely and persistently itchy skin disorders in aged patients should be investigated for BP diagnosis.


Subject(s)
Pemphigoid, Bullous/diagnosis , Age Factors , Aged , Aged, 80 and over , Diagnosis, Differential , Female , Humans , Male , Middle Aged , Pemphigoid, Bullous/complications , Pemphigoid, Bullous/therapy , Pruritus/etiology , Pruritus/pathology , Retrospective Studies , Risk Factors , Symptom Assessment
5.
J Nephrol ; 33(6): 1309-1319, 2020 Dec.
Article in English | MEDLINE | ID: mdl-32880884

ABSTRACT

BACKGROUND: The impact of cancer on death of elderly kidney transplant recipients has been extensively investigated, but with conflicting results. Unlike their younger counterparts, in elderly kidney transplant recipients cardiovascular and infectious disease may outweigh cancer in causing the patient's death. METHODS: Using competing risk analysis on a large retrospective cohort of kidney transplant recipients, we estimated the cause-specific cumulative incidence and hazard of death in different age categories and calculated standardized mortality ratios (SMRs) to compare mortality rates with the general population. RESULTS: Six thousand seven hundred eighty-nine kidney transplant recipients were followed-up for a median of 9 years. Ten years after transplantation, in transplant recipients aged 20-39, 40-59, and 60+, the cumulative incidence of cancer-related death was 0.6 (95% confidence interval [CI]: 0.3-1.0), 2.9 (2.3-3.6) and 5.3% (3.5-7.5), whereas the SMR was 9.1 (5.5-15.0), 2.0 (1.6-2.5), and 0.8 (0.6-1.0), respectively. At variance with young recipients, the hazard and the cumulative incidence of cardiovascular-related death in elderly recipients was well above that of cancer-related death. CONCLUSIONS: Relative to the general population, cancer-related death is increased in young but not in elderly kidney transplant recipients because of the more marked increased incidence of competing cause of death in the latter category.


Subject(s)
Kidney Transplantation , Neoplasms , Aged , Humans , Kidney Transplantation/adverse effects , Neoplasms/epidemiology , Retrospective Studies , Risk Assessment , Risk Factors , Transplant Recipients
7.
Eur J Dermatol ; 28(1): 44-49, 2018 Feb 01.
Article in English | MEDLINE | ID: mdl-29171395

ABSTRACT

BACKGROUND: Primary cutaneous lymphomas (PCLs) are a rare group of extranodal non-Hodgkin lymphomas, and epidemiological data in Mediterranean countries are scarce. OBJECTIVE: To investigate the incidence and characteristics of PCL in a single tertiary referral centre in Italy. MATERIALS & METHODS: A total of 141 PCL patients, seen over a 10-year follow-up period, were investigated. RESULTS: Incidence rate of PCL was 0.8 cases/100,000 person years. T-cell lymphoma represented 78.7% of all cases, the majority being early mycosis fungoides (MF) (64%; median age: 66 years), followed by lymphomatoid papulosis (LyP) (19%; median: age 48 years), and others (median age: 72 years), including eight cases of anaplastic large CD30+ T-cell lymphoma, four CD4+ small-medium pleomorphic T-cell lymphoproliferative disorder, four Sézary syndrome, one subcutaneous panniculitis-like T-cell lymphoma, one extranodal NK/T-cell lymphoma nasal-type, and one angioimmunoblastic T-cell lymphoma. B-cell lymphoma accounted for 21.3% of PCL, with 20 cases of cutaneous follicular centre B-cell (median age: 63 years), four primary cutaneous marginal zone, three primary cutaneous diffuse large B-cell, and three leg-type lymphoma. Complete remission within the first year after diagnosis occurred in 70.4% of MF, 61.9% of LyP, 78.9% of other T-cell lymphoma, and 93.1% of B-cell lymphoma cases. Based on a Cox proportional hazard regression model, age, gender, stage, and lactate dehydrogenase and ß2-microglobulin blood levels did not predict clinical remission of MF or LyP. CONCLUSIONS: The incidence and characteristics of PCL in Italy are similar to those in other European countries. PCLs may be diagnosed at very early stages with good prognosis.


Subject(s)
Lymphoma, T-Cell, Cutaneous/epidemiology , Skin Neoplasms/epidemiology , Adult , Age Distribution , Aged , Aged, 80 and over , Female , Follow-Up Studies , Humans , Incidence , Italy/epidemiology , Kaplan-Meier Estimate , Lymphoma, B-Cell/epidemiology , Lymphoma, T-Cell, Cutaneous/immunology , Lymphoma, T-Cell, Cutaneous/pathology , Male , Middle Aged , Mycosis Fungoides/epidemiology , Mycosis Fungoides/immunology , Mycosis Fungoides/pathology , Prognosis , Retrospective Studies , Sex Distribution , Skin Neoplasms/immunology , Skin Neoplasms/pathology , Time Factors
8.
Am J Transplant ; 18(5): 1220-1230, 2018 05.
Article in English | MEDLINE | ID: mdl-29024374

ABSTRACT

Organ transplant recipients (OTRs) have a 100-fold increased risk of cutaneous squamous cell carcinoma (cSCC). We prospectively evaluated the association between ß genus human papillomaviruses (ßPV) and keratinocyte carcinoma in OTRs. Two OTR cohorts without cSCC were assembled: cohort 1 was transplanted in 2003-2006 (n = 274) and cohort 2 was transplanted in 1986-2002 (n = 352). Participants were followed until death or cessation of follow-up in 2016. ßPV infection was assessed in eyebrow hair by using polymerase chain reaction-based methods. ßPV IgG seroresponses were determined with multiplex serology. A competing risk model with delayed entry was used to estimate cumulative incidence of histologically proven cSCC and the effect of ßPV by using a multivariable Cox regression model. Results are reported as adjusted hazard ratios (HRs). OTRs with 5 or more different ßPV types in eyebrow hair had 1.7 times the risk of cSCC vs OTRs with 0 to 4 different types (HR 1.7, 95% confidence interval 1.1-2.6). A similar risk was seen with high ßPV loads (HR 1.8, 95% confidence interval 1.2-2.8). No significant associations were seen between serum antibodies and cSCC or between ßPV and basal cell carcinoma. The diversity and load of ßPV types in eyebrow hair are associated with cSCC risk in OTRs, providing evidence that ßPV is associated with cSCC carcinogenesis and may present a target for future preventive strategies.


Subject(s)
Carcinoma, Squamous Cell/etiology , Eyebrows/virology , Organ Transplantation/adverse effects , Papillomaviridae/pathogenicity , Papillomavirus Infections/complications , Skin Neoplasms/etiology , Antibodies, Viral/blood , Carcinoma, Squamous Cell/pathology , Case-Control Studies , DNA, Viral/genetics , Female , Follow-Up Studies , Humans , Male , Middle Aged , Papillomaviridae/genetics , Papillomavirus Infections/pathology , Papillomavirus Infections/virology , Prognosis , Prospective Studies , Skin Neoplasms/pathology , Transplant Recipients , Viral Load
9.
Exp Dermatol ; 26(8): 733-736, 2017 08.
Article in English | MEDLINE | ID: mdl-27761950

ABSTRACT

Several association studies and GWAS on melanoma skin cancer risk have reported statistically significant signals on 9p21.3 region, where MTAP gene maps. None of the associated SNPs identified in these studies lie in the coding region of the gene and the causative relation of risk alleles with melanoma predisposition has not been elucidated. MTAP has a tumor suppressor activity and epigenetic silencing has been described in melanoma cell lines. In the present study, we show that melanoma risk alleles correlate with a MTAP allele-specific hyper-methylation and down-regulation of gene expression.


Subject(s)
Fibroblasts/metabolism , Melanoma/genetics , Purine-Nucleoside Phosphorylase/genetics , Allelic Imbalance , Case-Control Studies , CpG Islands , DNA Methylation , Haplotypes , Humans , Purine-Nucleoside Phosphorylase/metabolism
11.
G Ital Dermatol Venereol ; 151(5): 467-72, 2016 Oct.
Article in English | MEDLINE | ID: mdl-26381461

ABSTRACT

BACKGROUND: Filler injection is widely used for facial rejuvenation. Global skin rejuvenation requires the precise sequential injections of different areas, but a standardized and reproducible method is lacking. The purpose of the study was to develop a new method for a precise measurement of the degree of facial defect before and after full-face rejuvenation with injectable fillers, so called facial filler (FAFI) grid. METHODS: Three hundreds patients were included. There were 76 males and 224 females with a median age of 30.5 years. A grid of horizontal and vertical lines was drawn on the patients' face with a rigid meter and a surgical pen to identify some precise areas for sequential filler injections. The grid was also used to measure the defects and the corrections obtained. Three different formulations of hyaluronic acid were used for treating specific facial areas. RESULTS: Correction was judged adequate in 77% and 90% of cases by the physician and patients, respectively. Prevalence of adverse events was 8.8%, with mostly mild, with resolution in few weeks. CONCLUSIONS: FAFI grid proved to be helpful in guiding sequential injections for total facial rejuvenation.


Subject(s)
Cosmetic Techniques , Dermal Fillers/administration & dosage , Face/anatomy & histology , Hyaluronic Acid/administration & dosage , Adult , Cohort Studies , Dermal Fillers/adverse effects , Female , Humans , Hyaluronic Acid/adverse effects , Injections , Male , Middle Aged , Rejuvenation , Reproducibility of Results , Skin Aging/drug effects , Treatment Outcome
12.
Intern Emerg Med ; 10(2): 135-41, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25164408

ABSTRACT

Identification of pre-transplant factors influencing delayed graft function (DGF) could have an important clinical impact. This could allow clinicians to early identify dialyzed chronic kidney disease (CKD) patients eligible for special transplant programs, preventive therapeutic strategies and specific post-transplant immunosuppressive treatments. To achieve these objectives, we retrospectively analyzed main demographic and clinical features, follow-up events and outcomes registered in a large dedicated dataset including 2,755 patients compiled collaboratively by four Italian renal/transplant units. The years of transplant ranged from 1984 to 2012. Statistical analysis clearly demonstrated that some recipients' characteristics at the time of transplantation (age and body weight) and dialysis-related variables (modality and duration) were significantly associated with DGF development (p ≤ 0.001). The area under the receiver-operating characteristic (ROC) curve of the final model based on the four identified variables predicting DGF was 0.63 (95 % CI 0.61, 0.65). Additionally, deciles of the score were significantly associated with the incidence of DGF (p value for trend <0.001). Therefore, in conclusion, in our study we identified a pre-operative predictive model for DGF, based on inexpensive and easily available variables, potentially useful in routine clinical practice in most of the Italian and European dialysis units.


Subject(s)
Delayed Graft Function/complications , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/therapeutic use , Kidney Transplantation/statistics & numerical data , Adolescent , Adult , Aged , Allografts/growth & development , Female , Humans , Kidney/physiopathology , Male , Middle Aged , Retrospective Studies , Risk Factors
13.
J Dermatolog Treat ; 24(6): 458-62, 2013 Dec.
Article in English | MEDLINE | ID: mdl-23767411

ABSTRACT

Prurigo nodularis (PN) is a chronic, highly pruritic condition characterized by the presence of hyperkeratotic, excoriated, pruritic papules and nodules, with a tendency to symmetrical distribution. No reliable data exist about incidence and prevalence of PN in the general population, but it seems to be more frequent and more intense in females. PN may be associated with many dermatological and non-dermatological comorbidities, including psychiatric disease. Recent findings suggest a neuropathic origin of PN, with alterations in the dermal and epidermal small diameter nerve fibers. PN may have a tremendous impact on the quality of life, and few effective treatment options are available. Few randomized controlled trials (RCT) on the therapy of PN are available, demonstrating the efficacy of phototherapy alone or with psoralen, and of topical calcipotriol and topical steroids in occlusive medications. Thalidomide may be effective, but no RCT are available and its use is impractical due to the unfavorable safety profile. Gabapentin, pregabalin and the neurokinin receptor 1 antagonist, aprepitant, seem also to be effective in the therapy of PN, but RCTs are still lacking.


Subject(s)
Prurigo/etiology , Prurigo/therapy , Amines , Chronic Disease , Cyclohexanecarboxylic Acids , Dermatologic Agents/therapeutic use , Epidermis/innervation , Female , Gabapentin , Glucocorticoids/therapeutic use , Humans , Immunosuppressive Agents/therapeutic use , Male , Physical Therapy Modalities , Pregabalin , Prurigo/pathology , Sex Factors , Skin/innervation , gamma-Aminobutyric Acid/analogs & derivatives
14.
Dermatitis ; 23(6): 275-80, 2012.
Article in English | MEDLINE | ID: mdl-23169209

ABSTRACT

BACKGROUND: Prevalence and causes of allergic contact dermatitis (ACD) in children vary with time and geographical area. OBJECTIVE: This study aimed to determine the relevant allergens causing ACD in children and the relation between ACD and atopic dermatitis (AD). METHODS: A cohort study on 349 children (0-15 years old) patch tested over a 7-year period was conducted. RESULTS: Patch test results were positive for at least 1 allergen in 69.3% of patients and were relevant in 69.8%. The highest sensitization rate (76.7%) was observed in children who are 0 to 5 years old (n = 86, 64% females), followed by the group of 6- to 10-year olds (70%, n = 157, 47.8% females), whereas 62.3% of 11- to 15-year-old children (n = 106, 59.4%) were sensitized. The most frequent allergens were nickel (16.3%), cobalt (6.9%), Kathon CG (5.4%), potassium dichromate (5.1%), fragrance mix (4.3%), and neomycin (4.3%). Body areas mostly affected were upper limbs and hands (31%). Approximately one third of children also had AD. Allergic contact dermatitis was more widespread in children with AD. Patch tests resulted positive in 55.3% (50% relevant) of AD compared with 76.9% (77.5% relevant) of the children without AD. Sensitizers were similar to children without AD. CONCLUSIONS: Very young children showed a high rate of relevant positive patch test reactions to common haptens. Allergic contact dermatitis may easily coexist with AD.


Subject(s)
Allergens , Dermatitis, Allergic Contact/diagnosis , Dermatitis, Allergic Contact/epidemiology , Patch Tests/statistics & numerical data , Severity of Illness Index , Adolescent , Age Distribution , Allergens/adverse effects , Child , Child, Preschool , Cohort Studies , Coloring Agents/adverse effects , Cosmetics/adverse effects , Female , Humans , Infant , Infant, Newborn , Male , Metals/adverse effects , Patch Tests/methods , Perfume/adverse effects , Risk Assessment
15.
Dermatol Surg ; 38(10): 1622-30, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22805312

ABSTRACT

BACKGROUND: Nonmelanoma skin cancers (NMSC) are the most frequently observed cancers in solid organ transplant recipients (SOTR) and may have a significant disease burden. OBJECTIVE: To provide an update regarding the epidemiology and management of NMSC in SOTR. RESULTS: Ten-year incidence rates range from 10% in Italy to 20% in Northern Europe to 70% in Australia. More than 50% of NMSC are located on sun-exposed areas (head, dorsum of hands). Many risk factors have been identified, including age at transplantation, fair skin, type of immunosuppressive drugs, cumulative sun exposure, viral infections, and various genetic markers. Patients with a first NMSC have a 49 times higher risk of developing a subsequent NMSC. Skin self-examination and photoprotection should be encouraged in all transplanted patients. Long-term skin surveillance, early diagnosis and aggressive treatment of any suspicious lesion, reduction of immunosuppressive therapy, and conversion to m-TOR inhibitors can be also effective measures for reduction of NMSC incidence. CONCLUSIONS: NMSC is the most frequent cancer observed in SOTR. Early diagnosis, patient education, and modification of immunosuppression are effective measures for reduction of NMSC incidence.


Subject(s)
Carcinoma, Basal Cell/etiology , Carcinoma, Squamous Cell/etiology , Organ Transplantation/adverse effects , Skin Neoplasms/etiology , Carcinoma, Basal Cell/epidemiology , Carcinoma, Basal Cell/prevention & control , Carcinoma, Squamous Cell/epidemiology , Carcinoma, Squamous Cell/prevention & control , Humans , Immunosuppressive Agents/adverse effects , Keratosis, Actinic/drug therapy , Keratosis, Actinic/epidemiology , Patient Education as Topic , Population Surveillance , Risk Factors , Skin Neoplasms/epidemiology , Skin Neoplasms/prevention & control
16.
Dermatology ; 224(1): 31-7, 2012.
Article in English | MEDLINE | ID: mdl-22456343

ABSTRACT

BACKGROUND: The relative risk of psoriasis and its severity are directly related to the body mass index. OBJECTIVE: To investigate the effects of a hypoenergetic diet to maintain disease remission in obese patients. METHODS: A questionnaire was administered to 200 patients with moderate-to-severe chronic plaque psoriasis asking whether diet could influence psoriasis severity. Forty-two obese patients in remission (PASI improvement ≥75%) for at least 12 weeks after methotrexate therapy were randomly assigned to receive a hypocaloric diet or free diet for 24 weeks, and were then followed up for an additional 12 weeks. RESULTS: Most of the patients considered that a diet regimen could influence their psoriasis, and desired to enter a dietary program. Obese patients who were in disease remission and entered a hypocaloric diet regimen showed a significant body weight reduction after 12 weeks which was maintained at week 24. However, patients under hypocaloric and free diets did not significantly differ in the maintenance of psoriasis remission, with relapse observed already at week 12, but with a trend in favor of the intervention group. CONCLUSIONS: Body weight reduction alone may not be sufficient for maintaining remission of moderate-to-severe psoriasis in obese patients.


Subject(s)
Dermatologic Agents/therapeutic use , Methotrexate/therapeutic use , Obesity/diet therapy , Psoriasis/drug therapy , Adult , Aged , Body Mass Index , Diet, Reducing/methods , Female , Humans , Male , Middle Aged , Obesity/complications , Psoriasis/complications , Severity of Illness Index , Surveys and Questionnaires , Time Factors , Treatment Outcome , Weight Loss
17.
Med Microbiol Immunol ; 201(2): 117-25, 2012 May.
Article in English | MEDLINE | ID: mdl-21792749

ABSTRACT

There is increasing evidence of an association between human papillomaviruses (HPV) of the beta-genus (beta-PV) and the development of cutaneous squamous cell carcinoma (SCC). The viral DNA load may be an important determinant of pathogenicity, but there are currently no baseline epidemiological data relating to load in people without SCC. We investigated DNA-loads of eight beta-PV types previously associated with risk of SCC. We collected eyebrow hairs from immunocompetent people (ICP) and organ transplant recipients (OTR), determined load by quantitative PCR and obtained demographic, phenotypic, and sun exposure information. Viral loads for ICP from Australia (n = 241) and Italy (n = 223) and OTR from across Europe (n = 318) spanned seven orders of magnitude. The median loads for all types were below one viral DNA copy per 60 cells and were highest for HPV5, HPV8 and HPV20. None of the populations had consistently higher viral loads for all 8 types. However, a higher proportion of OTR were in the top deciles of viral load distributions for six of the eight beta-PV types examined. In a nested analysis of Italian OTR and ICP, this finding was significant for six beta-PV types and cumulative load. Increasing age was significantly associated with higher viral loads in Australia, and there was a weak trend for higher loads with the time elapsed since transplantation in the OTR. We observed a wide distribution of beta-PV loads with OTR significantly more likely to have the highest viral loads. Thus, viral loads may be an important contributor to the higher risk of SCC in OTR.


Subject(s)
Betapapillomavirus/isolation & purification , DNA, Viral/isolation & purification , Hair Follicle/virology , Viral Load , Aged , Aged, 80 and over , Australia , Betapapillomavirus/classification , Betapapillomavirus/genetics , Case-Control Studies , Data Collection , Europe , Eyebrows/virology , Female , Genotype , Humans , Immunocompromised Host , Male , Middle Aged , Real-Time Polymerase Chain Reaction , Transplants
18.
J Clin Rheumatol ; 17(8): 432-5, 2011 Dec.
Article in English | MEDLINE | ID: mdl-22089994

ABSTRACT

Leprosy is a chronic granulomatous disease caused by Mycobacterium leprae. We describe the case of a 20-year-old man from India living in Italy since 2003, who presented with erythematous papules and nodules distributed on his arms, legs, and face in 2006. He also had episodes of high fever, polyarthritis, and episcleritis. Sarcoidosis was suspected on the basis of elevated angiotensin-converting enzyme and bronchoalveolar lavage fluid, and the patient was treated with corticosteroids for about a year. A flare of the disease occurred each time corticosteroid was tapered or suspended. An autoinflammatory disease was then suspected and treated with immunosuppressant. Only the third deep skin biopsy revealed the presence of M. leprae. The lack of clinical suspicion and the unfamiliarity with the histology of leprosy delayed diagnosis and treatment. Leprosy should be considered in the differential diagnoses of patients presenting with rheumatic and cutaneous manifestations especially when they come from countries where the disease is endemic.


Subject(s)
Autoimmune Diseases/diagnosis , Diagnostic Errors , Leprosy/diagnosis , Mycobacterium leprae/isolation & purification , Sarcoidosis, Pulmonary/diagnosis , Still's Disease, Adult-Onset/diagnosis , Adrenal Cortex Hormones/administration & dosage , Autoimmune Diseases/drug therapy , Diagnosis, Differential , Humans , Leprosy/drug therapy , Leprosy/microbiology , Male , Sarcoidosis, Pulmonary/drug therapy , Still's Disease, Adult-Onset/drug therapy , Tomography, X-Ray Computed , Young Adult
19.
Exp Dermatol ; 20(12): 1025-7, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21995456

ABSTRACT

To define the potential involvement of polymorphisms in the 3'untranslated region (3'UTR) of the prostaglandin synthetase-2 (PTGS-2) gene to non-melanoma skin cancer (NMSC) predisposition after transplantation, we screened for genetic variant, relevant parts of this region. It contains binding sites for trans-acting factors, an alternative polyadenylation site and putative target sequences for miRNAs. Variant +8473T>C did not appear to play a functional role in the regulation of gene expression in human keratinocyte-transfected cells. In addition to the well-known +8473T>C, we identified four polymorphisms: +8293G>C, +10259T>G, +10267G>A and +10335G>A. No allele frequency differences were observed between cases and controls neither for +8473T>C nor for any of the identified polymorphisms, suggesting that polymorphisms in the 3'UTR of the PTGS2 gene are rare and unlikely to represent risk factor for NMSC after transplantation.


Subject(s)
3' Untranslated Regions/genetics , Cyclooxygenase 2/genetics , Organ Transplantation/adverse effects , Skin Neoplasms/genetics , Bowen's Disease/etiology , Bowen's Disease/genetics , Carcinoma, Basal Cell/etiology , Carcinoma, Basal Cell/genetics , Carcinoma, Squamous Cell/etiology , Carcinoma, Squamous Cell/genetics , Gene Expression/genetics , Gene Frequency/genetics , Genotype , Humans , Keratoacanthoma/etiology , Keratoacanthoma/genetics , Polymorphism, Single Nucleotide/genetics , Skin Neoplasms/etiology
20.
Am J Clin Dermatol ; 11(6): 399-411, 2010 Dec 01.
Article in English | MEDLINE | ID: mdl-20866115

ABSTRACT

Chronic pruritus is a major and distressing symptom of many cutaneous and systemic diseases and can significantly impair the patient's quality of life. Pruritus perception is the final result of a complex network involving dedicated nerve pathways and brain areas, and an increasing number of peripheral and central mediators are thought to be involved. Itch is associated with most cutaneous disorders and, in these circumstances, its management overlaps with that of the skin disease. Itch can also occur without associated skin diseases or primary skin lesions, but only with nonspecific lesions secondary to rubbing or scratching. Chronic itch with no or minimal skin changes can be secondary to important diseases, such as neurologic disorders, chronic renal failure, cholestasis, systemic infections, malignancies, and endocrine disorders, and may also result from exposure to some drugs. The search for the cause of pruritus usually requires a meticulous step-by-step assessment involving careful history taking as well as clinical examination and laboratory investigations. Few evidence-based treatments for pruritus are available. Topical therapy, oral histamine H(1) receptor antagonists, and phototherapy with UV radiation can target pruritus elicitation in the skin, whereas antiepileptic drugs, opioid receptor antagonists, and antidepressants can block signal processing in the CNS.


Subject(s)
Pruritus , Adrenal Cortex Hormones/therapeutic use , Anticonvulsants/therapeutic use , Antidepressive Agents/therapeutic use , Antipruritics/therapeutic use , Chronic Disease , Emollients/therapeutic use , Histamine Antagonists/therapeutic use , Humans , Narcotic Antagonists/therapeutic use , Phototherapy , Pruritus/diagnosis , Pruritus/etiology , Pruritus/physiopathology , Pruritus/therapy , Skin/innervation , Skin/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL